BIOXYTRAN, INC
For the period ended Mar 2, 2026. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 2, 2026 · Filed Mar 2, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Development Context
Development Context
ProLectin-M is designed to target galectins, carbohydrate-binding proteins that certain viruses utilize to attach to and enter host cells. By acting on host-virus interactions rather than intracellular viral replication, this approach represents a differentiated antiviral strategy that may have applicability across multiple viral infections. In future studies, ProLectin-M may also be evaluated for its potential as a preventive therapy. The Company believes these results support continued evaluation of ProLectin-M as a potential oral therapeutic and provide a foundation for future clinical studies.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.